Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.48 |
| ▸ | DRD3 | P35462 | 8/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496072 | 0.87 | GPR119 (0.54) | DRD2DRD3VCP | |
| SCHEMBL3845038 | 0.87 | DRD2 (0.47) | DRD2DRD3SLC6A2SLC6A4VCP | |
| SCHEMBL3849039 | 0.84 | DRD2 (0.49) | DRD2DRD3VCPHTR1A | |
| SCHEMBL17226505 | 0.82 | VCP (0.44) | DRD2DRD3SLC6A2SLC6A4VCP | |
| SCHEMBL3844622 | 0.80 | DRD2 (0.49) | DRD2DRD3 | |
| SCHEMBL4500313 | 0.79 | CHRM4 (0.58) | DRD2DRD3CHRM4 | |
| SCHEMBL3853613 | 0.79 | DRD2 (0.53) | DRD2DRD3HTR1A | |
| SCHEMBL4491079 | 0.78 | DRD2 (0.57) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL17219816 | 0.78 | DRD2 (0.56) | DRD2DRD3 | |
| SCHEMBL3849915 | 0.78 | MAPT (0.49) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |